Refine by MP, party, committee, province, or result type.

Results 1-15 of 229
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  Well, I'm happy to answer again. Just quickly, we in the generic pharmaceutical industry have worked throughout this very closely with distributors and pharmacies in Canada, and with our own member companies. Our own member companies are, as was said, required to report all short

July 6th, 2020Committee meeting

Jim Keon

Health committee  The issue of drug shortages has been an issue, for the last five years and more, worldwide. It's not just a Canadian issue. I think part of it has been the interaction of increased regulatory scrutiny around the world. Agencies have gone to locations where they hadn't before. I t

July 6th, 2020Committee meeting

Jim Keon

Health committee  Yes, we have the largest R and D company in Canada, as Peter mentioned. We also have the largest company in Quebec. I think that while we are focused on the vaccine, our message today is we have thought about this. We put out a blueprint on how we ensure that three-quarters of th

July 6th, 2020Committee meeting

Jim Keon

Health committee  I won't speak for Gilead because they're not a member of our group, but in general the trials on remdesivir are ongoing. It appears that it has had some effect in reducing the morbidity of COVID-19, so that's excellent. I think when the approvals are forthcoming stating that it i

July 6th, 2020Committee meeting

Jim Keon

Health committee  We've been clear. The commitment on intellectual property has not been reached for many years now. I think that's a matter for IMC to address with the government. We have particularly raised this point when there have been discussions in international trade agreements, where cou

July 6th, 2020Committee meeting

Jim Keon

Health committee  Yes, we made that comment. The government moved with emergency measures in March when the COVID shock first hit. I think while we support that legislation, to be very honest, it has not been our focus. Our focus has been on the 75% of the medicines that we are now producing and t

July 6th, 2020Committee meeting

Jim Keon

Health committee  Thanks, Peter. I know the clerk has circulated to members a summary of the CGPA blueprint for a sustainable supply of prescription medicines for Canadians. The CGPA developed this blueprint based on some of the lessons learned during the first three months of the pandemic. It ou

July 6th, 2020Committee meeting

Jim Keon

International Trade committee  That is true. The Europeans were pushing for a five-year extension, which would have been a 25-year patent. The CETA negotiators managed to mitigate that, to reduce it to a two-year extension. That's what the bill says, and we believe it should be no longer than that. As for the

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That's correct.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  Well, that's just maintaining what we can already do, because right now, after 20-year patents expire, we can manufacture, so we can export. This means that during that two-year period, we can manufacture for export.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That's a very good question. That is a really critical aspect of what we're hoping will happen as a result of CETA. That, as I mentioned earlier, is going to occur with regulatory changes that come under this patent-medicine notice-of-compliance regime. These regulations are incr

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  As I said, the most important aspect is that this be applied prospectively so that the impact will be down the road eight or ten years. The clear impact is that the low-cost generics are going to be delayed two years—that's what the legislation calls for—beyond what they are now,

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  With respect to retroactivity, the provisions of Bill C-30 should apply, in terms of this patent extension or certificates of supplementary protection, only to products approved after the coming into force of CETA. The amendment we have makes that absolutely clear, and I'm hoping

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  As I said, we're going to be delayed coming to market. The good thing about this is that there was an export clause negotiated as part of CETA. It is in the bill. That mitigates some of the impact. If that is done properly, we're going to continue to push very hard to get investm

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  Generic drug manufacturers are the primary manufacturers in the pharmaceutical industry. As I said, more than 11,000 people develop and manufacture products in Canada and export them to over 100 countries. With a 12-year extension of the patent, the challenges will be greater th

November 29th, 2016Committee meeting

Jim Keon